The PI3K inhibitor wortmannin nearly completely blocked cell proliferation and resistance to doxorubicin in MCF-7/ADR (ADR: Adriamycin resistance) breast cancer cells (Tsou et al., 2015). Here, PIK3CB is linked to breast cancer.